PWE-132 Therapeutic outcomes following endotherapy for refractory gastroparesis

    loading  Checking for direct PDF access through Ovid



The relative merits of endotherapy for refractory gastroparesis remain unclear. We assessed the symptomatic response of patients undergoing non-surgical pyloric intervention at a specialist tertiary centre.


57 patients (21 male, mean age 47, 16–81) with medical refractory gastroparesis (29 idiopathic, 5 diabetic, 23 post-gastric transposition) underwent 117 endoscopic treatments from Sep 2013-Sep 2017: either 100IU units of Botox injected into 4 quadrants of the pylorus (n≥66), balloon dilatation to 15–20 mm (EBD, n≥13) or combination therapy (n≥38). Patients with gastric malignancy, pyloric surgery or no follow-up were excluded. Symptoms were assessed immediately prior to each procedure and at first follow up using a retrospective scoring system based on the presence (1 point) or absence (0 points) of Vomiting, Nausea, Bloating or Early satiety. This formulated a composite symptom score (SS) out of 4; positive response was defined by improvement in SS of at least 1. Statistical analysis was performed using Wilcoxon Signed-Rank Test and Fischer’s Test.


There were no immediate or late complications. Mean symptom score (SS) improved per-patient from 2.1 points at baseline to 1.2 post initial endotherapy(p<0.01) at median follow up of 2.1 months. 20 patients required further endotherapy (median 2.5 treatments; range 2–12); mean SS was 1.0 at latest follow-up.


Per-procedure, mean reduction in SS was 0.8 points (p<0.01) with overall positive response rate of 67%. By symptom, vomiting was most responsive to endotherapy (86% pre v 32% post). By treatment type, Botox alone (n≥66) had the highest overall response (78%) compared to EBD (38%, p≥0.02) or combination therapy (66%, p≥0.3). Response to Botox was greater in patients under 40 (83% v 61%, p≥0.04) and females (81% v 33%, p≥0.002). By indication, diabetic GP(n≥17) were most likely to respond (76%).


Sub-group analysis showed procedures for gastroparesis (diabetic/idiopathic, n≥75) responded significantly more to Botox (mean SS reduction 1, p<0.01) than EBD (mean SS reduction 0.2, p>0.1) or combination therapy (mean SS reduction 0.44, p≥0.12). Procedures for gastric transposition(n≥42) showed significant SS reduction post combination therapy (2.1 v 1.2, p≥0.01) but not post EBD (1.9 v 1.6, p>0.1) or Botox (1.7 v 1.1, p≥0.08).


Endotherapy is a safe and effective treatment for refractory gastroparesis. We found Botox monotherapy significantly improved symptoms in diabetic or idiopathic gastroparesis, especially younger females; conversely, combination therapy was preferable for delayed gastric emptying post gastric transposition. Careful patient selection may augment therapeutic response.

Related Topics

    loading  Loading Related Articles